Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cordyceps sinensis for Prevention of MAC-PD Recurrence
NCT07174076Phase 4Recruiting
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in mycobacterium avium complex pulmonary disease (MAC-PD) comparing Cordyceps sinensis with Placebo (2 arms). Primary endpoint: bacterial recurrence of MAC-PD at 12 months. Started Jul 2025; status: recruiting.
02
Drugs
cordyceps sinensis
03
Conditions
mycobacterium avium complex pulmonary disease (MAC-PD)
Beyond the preview
Go deeper on NCT07174076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174076.